Drug Safety Monitoring Systems

## Overview

Clinical trials typically enroll 1,000-3,000 patients, which means adverse drug reactions occurring at rates below 1:1,000 are unlikely to be detected before approval. Post-marketing pharmacovigilance is the systematic monitoring of drug safety after a product reaches the market, where millions of patients with diverse comorbidities and comedications are exposed.

## Spontaneous Reporting Systems

**FDA FAERS (Adverse Event Reporting System)** is the primary US system for post-marketing surveillance. Healthcare professionals, consumers, and manufacturers submit reports of suspected adverse events. FAERS receives over 2 million reports annually. Reports are voluntary for clinicians and mandatory for manufacturers. The major limitation is underreporting — an estimated 1-10% of serious ADRs are reported.

**MedWatch** is the FDA's safety reporting portal for healthcare professionals and patients. It accepts reports for drugs, biologics, medical devices, and dietary supplements. Reports feed into FAERS.

**WHO VigiBase** is the world's largest pharmacovigilance database, maintained by the Uppsala Monitoring Centre. It aggregates individual case safety reports (ICSRs) from over 170 member countries, containing over 30 million reports. VigiBase enables global signal detection that would be impossible from national databases alone.

**EudraVigilance** is the European Medicines Agency's system, receiving reports from all EU/EEA member states. It became publicly accessible in 2018, increasing transparency.

## Signal Detection Methods

**Disproportionality analysis** compares the observed reporting rate of a drug-event combination to the expected rate based on all reports in the database. Metrics include the Proportional Reporting Ratio (PRR), Reporting Odds Ratio (ROR), and Bayesian methods (BCPNN, MGPS). A "signal" is generated when a drug-event pair is reported disproportionately more often than expected.

**Electronic health record (EHR) mining** analyzes real-world patient data from large healthcare systems. The FDA's Sentinel System actively monitors over 100 million patients across multiple healthcare databases, enabling rapid hypothesis testing when safety signals emerge.

## Risk Evaluation and Mitigation Strategies (REMS)

When a drug's benefits outweigh its risks but specific safety measures are needed, the FDA can require a REMS. Components may include:

- **Medication Guide**: Patient-directed information sheet
- **Communication Plan**: Healthcare provider education
- **Elements to Assure Safe Use (ETASU)**: Restricted prescribing, dispensing, or administration requirements (e.g., iPLEDGE for isotretinoin, TIRF REMS for transmucosal fentanyl)

## Key Regulatory Actions

When pharmacovigilance identifies serious risks, the FDA can issue safety communications, require labeling changes (boxed warnings), mandate post-marketing studies, restrict distribution, or withdraw the drug. Notable withdrawals include rofecoxib (cardiovascular events, 2004), troglitazone (hepatotoxicity, 2000), and cisapride (QT prolongation, 2000).

## Limitations and Future Directions

Spontaneous reporting suffers from underreporting, reporting bias, and inability to establish causation. Active surveillance systems (Sentinel), large observational databases, and artificial intelligence-driven signal detection are addressing these gaps. Patient-reported outcome integration and social media monitoring are emerging data sources.

## Key Takeaways

- Clinical trials detect only common ADRs; pharmacovigilance catches rare events post-marketing
- FAERS receives >2 million reports/year but only 1-10% of serious ADRs are reported
- WHO VigiBase aggregates >30 million reports from 170+ countries for global signal detection
- REMS programs add safety controls for high-risk drugs without removing them from market
- Active surveillance (FDA Sentinel) monitors 100+ million patients in real-world databases